Rituximab for Non-Hodgkins Lymphoma
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rituximab for Non-Hodgkins Lymphoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1029
Article Code: 1029c
Date: June 19, 1998
Volume: 40
Pages: 65-66
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1029
Article Code: 1029c
Date: June 19, 1998
Volume: 40
Pages: 65-66
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)